Literature DB >> 15847994

In vitro characterization of some biopharmaceutical properties of praziquantel.

Dinora González-Esquivel1, Julio Rivera, Nelly Castro, Lilian Yepez-Mulia, Helgi Jung Cook.   

Abstract

In several studies of patients with neurocysticercosis under treatment with praziquantel (PZQ), the pharmacokinetic data were difficult to interpret probably because of the low solubility as well as its variable oral bioavailability. Because there is limited information available regarding the biopharmaceutical properties of PZQ, the aim of this work was to evaluate the absorption characteristics of the drug and its dissolution behaviour in simulated media. Additionally, its in vitro protein binding and displacement by highly bound drugs was evaluated. Permeability evaluation was carried out by using Caco-2 cells. Dissolution release profiles were evaluated using the USP apparatus and the following dissolution media: HCl containing 2mg of sodium laurylsulfate per milliliter, milk, FeSSIF and FaSSIF. Protein binding of PZQ was carried out by equilibrium dialysis. Results showed that praziquantel was absorbed by passive diffusion. The apparent permeability constant value was 4.4x10(-5) cm/s. Binding was not influenced by the addition of highly bound drugs. Dissolution from a tablet formulation showed that the rate of praziquantel was dependent on the components of the media. Although the simulated media could explain the influence of the lipids on praziquantel absorption, they were not able to forecast the influence of carbohydrates. Further refinements are required to explain the in vivo data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847994     DOI: 10.1016/j.ijpharm.2005.01.033

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach.

Authors:  Luciana Damacena Silva; Nayana Ferreira Lima; Eva Carolina Arrua; Claudio Javier Salomon; Marina Clare Vinaud
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel.

Authors:  Stratos Maragos; Helen Archontaki; Panos Macheras; Georgia Valsami
Journal:  AAPS PharmSciTech       Date:  2009-12-01       Impact factor: 3.246

3.  Dissolution and oral bioavailability enhancement of praziquantel by solid dispersions.

Authors:  Yanyan Liu; Tianzi Wang; Wenya Ding; Chunliu Dong; Xiaoting Wang; Jianqing Chen; Yanhua Li
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

4.  Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.

Authors:  Gabriel Kigen; Geoffrey Edwards
Journal:  BMC Pharmacol Toxicol       Date:  2017-05-04       Impact factor: 2.483

5.  In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel.

Authors:  Nyasha Nicole Kapungu; Xueqing Li; Charles Nhachi; Collen Masimirembwa; Roslyn Stella Thelingwani
Journal:  Pharmacol Res Perspect       Date:  2020-08

6.  Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).

Authors:  Gabriel Kigen; Geoffrey Edwards
Journal:  BMC Pharmacol Toxicol       Date:  2016-08-14       Impact factor: 2.483

7.  A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing.

Authors:  Sören Frahm; Anisuzzaman Anisuzzaman; Ulrich Fabien Prodjinotho; Nermina Vejzagić; Admar Verschoor; Clarissa Prazeres da Costa
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.